Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer

被引：2
作者：
Wander, S. A.
Spring, L. M.
Stein, C. R.
Yuen, M.
Zangardi, M.
O'Shaughnessy, J.
Bardia, A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-18-39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-18-39
引用
收藏
页数：2
相关论文
共 50 条
[21]   Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2 Metastatic Breast Cancer [J].
Pluard, Timothy J. ;
Sandin, Rickard ;
Parikh, Rohan C. ;
Ward, Melea Anne ;
Stansfield, Lindsay ;
Nham, Tram ;
Esterberg, Elizabeth ;
Cha-Silva, Ashley S. ;
Shah, Bhavesh .
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2025, 17 :247-264
[22]   Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC) [J].
Tolaney, S. M. ;
Cortes, J. ;
Dickler, M. N. ;
Zamora, E. ;
Caldwell, C. W. ;
Nguyen, T. S. ;
Nanda, S. ;
Koustenis, A. ;
Rugo, H. S. .
ANNALS OF ONCOLOGY, 2016, 27
[23]   REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2-BREAST CANCER TREATED WITH PALBOCICLIB [J].
Montenegro, Maria Alexandra ;
Simao, Diana Cardoso ;
Mendes, Jose Leao ;
Fernandes, Leonor Raposo ;
Martins, Maria Manuela ;
Da Luz, Ricardo ;
Oliveira, Sonia Duarte .
BREAST, 2023, 71 :S57-S58
[24]   Abemaciclib for the treatment of HR+/HER2- breast cancer [J].
Exman, Pedro ;
Tolaney, Sara M. .
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03) :151-161
[25]   Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. [J].
Tolaney, Sara M. ;
Lin, Nancy U. ;
Thornton, Donald ;
Klise, Suzanne ;
Costigan, Timothy Michael ;
Turner, P. Kellie ;
Anders, Carey K. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[26]   Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer [J].
Ban, Marija ;
Mise, Branka Petric ;
Majic, Ana ;
Drazic, Ivanka ;
Vrdoljak, Eduard .
FUTURE ONCOLOGY, 2018, 14 (06) :537-544
[27]   Clinical characteristics, demographics, and outcomes in hormone-receptor (HR plus ) positive metastatic breast cancer (MBC) patients treated with palbociclib. [J].
Landry, Chrystal Ann ;
Dimitrova, Maya ;
Ru, Meng ;
Teplinsky, Eleonora ;
Tiersten, Amy .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28]   Management of abemaciclib associated adverse events in patients with hormone receptor positive (HR+), HER2-advanced breast cancer: Analysis of the MONARCH trials [J].
Rugo, H. S. ;
Tolaney, S. M. ;
Huober, J. ;
Toi, M. ;
Andre, V. ;
Barriga, S. ;
Forrester, T. ;
Sledge, G. W. ;
Goetz, M. P. .
ANNALS OF ONCOLOGY, 2018, 29
[29]   A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer [J].
Li, Allen ;
Naik, Arpana ;
Johnson, Nathalie ;
Goodyear, Shaun ;
Johnson, Brett ;
Park, Byung ;
Corless, Christopher ;
Gray, Joe ;
Mills, Gordon ;
Mitri, Zahi .
CANCER RESEARCH, 2021, 81 (04)
[30]   SG Improves OS in HR+/HER2-Breast Cancer [J].
Poh, Alissa .
CANCER DISCOVERY, 2022, 12 (12) :2714-2715
12345